8-K: Sonnet BioTherapeutics Announces Positive Phase 1b Data for SON-080, Plans Phase 2 Study in Diabetic Peripheral Neuropathy

Sonnet BioTherapeutics reported encouraging Phase 1b clinical trial data for SON-080 in Chemotherapy-Induced Peripheral Neuropathy, supporting advancement to a Phase 2 study in Diabetic Peripheral Neuropathy.

Summary

• Sonnet BioTherapeutics announced positive results from the Phase 1b portion of its Phase 1b/2a clinical trial of SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN).
• The data suggests that SON-080 was well-tolerated at both 20 g and 60 g doses, with no evidence of a pro-inflammatory cytokine response.
• Pain and quality of life survey results indicated a trend towards rapid improvement of peripheral neuropathy symptoms and post-dosing durability compared to placebo.
• The company intends to seek a partnership to support a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN).
• The Phase 1b study involved 9 patients randomized between two different SON-080 dose groups and a placebo group, with a 12-week treatment period and a 12-week follow-up.
• Injection site erythema was the most prominent treatment-related adverse event, and was generally mild and transient.
• A trend toward improved quality of life scores was observed within a month of starting therapy with SON-080, and this improvement persisted after the 12-week treatment period.
• There was a dose-related increase in serum amyloid alpha during therapy, which returned to baseline after treatment stopped, and was deemed benign by an expert consultant.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial data and a clear path forward for the company, indicating a strong positive sentiment. The company is actively seeking a partnership to fund the next phase of development, which is a positive sign for investors.

Positives

• SON-080 demonstrated good tolerability at both tested doses.
• The drug showed a trend towards rapid improvement in pain and quality of life scores.
• The positive effects of SON-080 appeared to persist even after the treatment period ended.
• The company is moving forward with a Phase 2 study in a larger, high-value indication (DPN).
• The adverse events were generally mild and manageable.
• The data supports the potential for SON-080 to address unmet medical needs in peripheral neuropathy.

Negatives

• Injection site erythema was the most prominent treatment-related adverse event.
• Fatigue was reported occasionally, with one patient in the low-dose group stopping treatment due to severe fatigue.
• There was a dose-related increase in serum amyloid alpha during therapy, although it was deemed benign.
• The number of patients in the study was small, which may limit the generalizability of the results.

Risks

• The Phase 2 study will require a partnership to move forward, which may not be secured.
• The positive trends observed in the Phase 1b study may not be replicated in larger clinical trials.
• The company is dependent on the success of SON-080 and its ability to secure funding for further development.
• The company is subject to the risks associated with clinical trials and regulatory approvals.
• The company is subject to the risks associated with the biotechnology industry, including competition and market volatility.

Future Outlook

The company intends to seek a partnership to support the initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN).

Management Comments

• Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer, stated that the data bridges the large atexakin alfa historical safety database and is foundational in advancing the development of SON-080 to a Phase 2 study.
• Richard Kenney, M.D., Sonnets Chief Medical Officer, commented that the use of SON-080 in CIPN was expected to provide a similar adverse event profile at low doses and that they now have a further understanding of the adverse event profile and the opportunity to look at preliminary efficacy trends.
• Gael Hedou, PhD, Chief Operating Officer, discussed the similarities between CIPN and DPN and the potential for SON-080 to be effective in DPN due to its role in improving blood flow and regulating glucose levels.

Industry Context

The announcement is relevant to the broader pharmaceutical industry, particularly in the areas of pain management and neuropathy treatments. The focus on DPN aligns with the industry's interest in addressing the high prevalence of neuropathy in diabetes. The company's approach of using low-dose IL-6 to stimulate nerve regrowth is a novel approach in the field.

Comparison to Industry Standards

• The use of low-dose IL-6 is a departure from traditional pain management approaches for neuropathy, which often rely on drugs like pregabalin, gabapentin, or antidepressants.
• The company's approach is based on preclinical models showing that low-dose IL-6 can stimulate nerve regrowth, which is different from the symptomatic relief provided by existing treatments.
• The company is leveraging the historical safety data of atexakin alfa, an earlier version of rhIL-6, to support the safety profile of SON-080.
• The company is targeting a larger market with DPN, which has a significant unmet medical need, compared to the smaller CIPN market.
• The company is seeking a partnership to fund the Phase 2 trial, which is a common strategy for smaller biotech companies.

Stakeholder Impact

• Shareholders may view the positive clinical trial data and the potential for a partnership as positive developments.
• Employees may be encouraged by the progress of the company's lead drug candidate.
• Patients with CIPN and DPN may benefit from the development of a new treatment option.
• Potential partners may be interested in the opportunity to collaborate on the development of SON-080.

Next Steps

• The company intends to seek a partnership to support the initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN).
• The DPN Phase 2 trial can be initiated in Australia when it is approved by the Australian Safety Committee.

Key Dates

Keywords

SON-080, Chemotherapy-Induced Peripheral Neuropathy, CIPN, Diabetic Peripheral Neuropathy, DPN, Interleukin-6, rhIL-6, Clinical Trial, Phase 1b, Phase 2, Neuropathy, Immunotherapeutic, Biotechnology, Partnership